首页 | 本学科首页   官方微博 | 高级检索  
检索        


High Dimensional Immune Profiling of Smoldering Multiple Myeloma Distinguishes Distinct Tumor Microenvironments
Institution:1. Precision Immunology Institute;2. Tisch Cancer Institute;3. Human Immune Monitoring Center;4. Department of Oncological Sciences, Icahn School of Medicine at Mt. Sinai, New York, NY;5. Multiple Myeloma Research Foundation, Norwalk, CT;6. Janssen Research & Development, LLC, Spring House, PA;1. University of Kansas Medical Center, Kansas City, KA;2. Levine Cancer Institute, Carolinas Healthcare System, Charlotte, NC;3. Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KA;4. Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI;5. Division of Pathology & Laboratory Medicine, University of Kansas Medical Center, Kansas City, KA;6. Division of Ophthalmology, University of Kansas Medical Center, Kansas City, KA;7. Division of Hematology & Hematologic Malignancies, University of Utah, Salt Lake City, UT;8. US Myeloma Research Consortium (USMRC, Kansas City, KA;1. Department of Dermatology, Icahn School of Medicine at Mount Sinai, 5 East 98th St, 5th Floor, New York, NY 10029;2. The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, 1190 One Gustave L. Levy Place, New York, NY, United States;1. Janssen Research & Development, 1400 McKean Road, Spring House, PA 19477, United States;2. Novartis Pharmaceuticals Corporation, 1 Health Plaza, East Hanover, NJ 07936, United States;3. Janssen Research & Development LLC, 3210 Merryfield Row, San Diego, CA 92121, United States;4. Genmab US, Inc., 902 Carnegie Center Blvd, Princeton, NJ 08540, United States;5. Jazz Pharmaceuticals, 3170 Porter Dr, Palo Alto, CA 94304, United States;6. Janssen Research & Development, Turnhoutseweg 30, 2340 Beerse, Belgium;7. Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065, United States
Abstract:BackgroundMultiple myeloma (MM) is a malignancy of plasma cells that arises from premalignant Monoclonal Gammopathy of Undetermined Significance (MGUS) and often progresses through an asymptomatic Smoldering (SMM) phase. Understanding the interactions between abnormal clonal plasma cells and the tumor microenvironment (TME) in the early disease states (MGUS, SMM) may inform risk assessment and therapy.Patients and MethodsWe performed high dimensional immunologic analysis of bone marrow specimens from 73 subjects with SMM by mass cytometry and T cell receptor sequencing of CD138-depleted bone marrow (BM) mononuclear cells, and proteomics and seromic profiling of BM plasma. Analysis of individual assay data identified self-organizing subgroups of SMM patients. We then applied novel bioinformatic methods to integrate data from pairs, trios, and quartets of assays.ResultsMass cytometry, TCRSeq and proteomics identified three taxa (sing. taxon) of subjects that shared common characteristics across all three assays. Differential levels of BM plasma pleiotropin (PTN) and BM T cells and their productive clonality emerged as strong distinguishing factors among these taxa.ConclusionThese results suggest that the continuum from MGUS to MM does not consist of a single pathway in the TME, and that complex interactions between myeloma cells and the TME may ultimately determine progression and inform clinical management.
Keywords:
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号